Aranda E, et al. - In metastatic colorectal cancer (mCRC) patients, researchers assessed mFOLFOX+cetuximab followed by maintenance mFOLFOX+cetuximab or single-agent cetuximab. The findings from this multicenter, randomized, phase 2 study suggested that maintenance therapy with single-agent cetuximab following mFOLFOX+cetuximab induction may be a valuable possibility vs continuing with mFOLFOX+cetuximab. It was found that progression-free survival (PFS) at 9 months was similar between cetuximab alone and FOLFOX+cetuximab. In addition, PFS and overall survival were similar between cetuximab alone and FOLFOX+cetuximab. Data reported that safety profile was also similar between cetuximab alone and FOLFOX+cetuximab, though cetuximab alone was correlated with less grade ≥III rash and sensory neuropathy and a lower rate of serious adverse events.